Clinical Trials Logo

Gastrointestinal Neoplasm clinical trials

View clinical trials related to Gastrointestinal Neoplasm.

Filter by:

NCT ID: NCT06159634 Recruiting - Clinical trials for Gastrointestinal Neoplasm

Traction vs. No Traction in Colonic ESD

Start date: December 5, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective, randomized, controlled trial conducted at Baylor St. Luke's Medical Center is to compare the effectiveness and clinical outcomes of using a traction device in colonic endoscopic submucosal dissection (ESD) to those of using conventional ESD. The investigators of this study hypothesize that use of the traction device will help expedite colonic endoscopic submucosal dissections.

NCT ID: NCT06134687 Not yet recruiting - Clinical trials for Gastrointestinal Neoplasm

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Start date: May 6, 2024
Phase: N/A
Study type: Interventional

The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame California, USA) device in comparison to conventional ESD. The research team hypothesize that with utilizing a novel rigidizing overtube the procedure time including dissection speed and closure time will be faster due to higher scope stability and greater control over the scope tip. Subsequently, the investigators anticipate lower immediate or delayed adverse events.

NCT ID: NCT05320029 Completed - Clinical trials for Gastrointestinal Neoplasm

Disposable Powered Articulating Linear Cutter Stapler in Gastrointestinal Tissue Cutting and Anastomosis

Start date: August 30, 2018
Phase: N/A
Study type: Interventional

To evaluate whether the anastomosis success rate of the main effectiveness evaluation indexes is not inferior to the similar products produced by Johnson & Johnson when the Fengh Disposable Powered Articulating Endoscopic Linear Cutter Stapler Used for Gastrointestinal Tissue Cutting and Anastomosis

NCT ID: NCT05172635 Completed - Clinical trials for Gastrointestinal Neoplasm

Primary Tumour Response to Induction Chemotherapy in Synchronously Metastasized Colorectal Cancer

Start date: June 1, 2014
Phase:
Study type: Observational

We performed a retrospective data analysis of patients with synchronously metastasized colorectal cancer, comparing the histological response on the primary tumour to chemotherapy combined with either vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) inhibition.

NCT ID: NCT03538613 Withdrawn - Clinical trials for Gastrointestinal Neoplasm

Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Start date: May 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Background: The gene CISH can weaken immune cells called lymphocytes. It is found in all cells of the body but it most negatively impacts lymphocytes. This study may help people with certain cancers.Lymphocyte cells will be taken from their tumors, the CISH gene will be removed from those cells, then the cells will be returned to the person. Researchers hope this process will help the cells work better and fight the tumors. Objective: To see if cells with the CISH gene removed are safe and shrink metastatic gastrointestinal epithelial tumors. Eligibility: People 18 70 years old with metastatic gastrointestinal epithelial cancer Design: Participants will be screened with physical exam, scans, and heart, lung, blood, and urine tests. Participants will have cells collected in another protocol. They must tell their doctor of any antibiotic allergy. The cells will be changed in a lab. Participants will stop therapy 4 6 weeks before getting the cells back. Participants will have leukapheresis. Blood is sent by a needle in one arm into a machine that takes out the white blood cells. The blood is returned through a needle in the other arm. Participants will have an IV catheter inserted in their upper chest to receive medicines and the cells. Participants will stay in the hospital and: - Have chemotherapy for 1 week - Get the cells for about a half hour to a little over an hour - Get a cell growth medicine about every 8 hours for up to 12 doses - Get medicines to boost blood cells and fight side effects - Recover for 1 3 weeks. Participants will have 2 follow-up visits within 12 weeks of treatment, then a couple visits each year. They will repeat screening tests.

NCT ID: NCT03411915 Completed - Clinical trials for Neuroendocrine Tumor

A Study of XmAb®18087 in Subjects With NET and GIST

Start date: January 22, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST. The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion cohorts to collect additional data on safety and potential efficacy of XmAb18087.

NCT ID: NCT02785783 Completed - Clinical trials for Gastrointestinal Disease

Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection

Erings™
Start date: May 13, 2016
Phase: N/A
Study type: Interventional

This study evaluates the impact of Endorings™ assisted colonoscopy on the number of polyps detected per patient compared to standard colonoscopy without use of EndoRings™. Half of the participants will receive EndoRings™ assisted colonoscopy, while the other half will receive standard colonoscopy.

NCT ID: NCT01621295 Completed - Melanoma Clinical Trials

Assessing the Patient Experience in Cancer Care

Start date: May 2012
Phase: N/A
Study type: Observational

Communication is an important component of comprehensive cancer care impacting patient satisfaction, adherence, and quality of life. The wide array of issues addressed in cancer clinical interactions makes communicating about a broad range of topics (including quality of life, communication, symptom control, complementary/alternative therapies, costs, treatment burden, prognosis, anxiety, side-effects, sexual function, palliative care options, etc.) especially interesting and potentially challenging. Some of these topics may not be routinely addressed in the clinical interaction or may require consultative support from other members of the comprehensive cancer care team. One frequently overlooked critical element in research on communication between cancer clinicians, their patients, and their primary care clinicians is describing real-time consultations between patients and their clinicians. These interactions provide rich material for assessing key psycho-social dynamics and identifying issues that patients find important in their care. In order to devise systems of care that optimize the patient experience, it is critical that clinicians and researchers understand, appreciate, and systematically characterize the richness and complexity of the decision-making process in routine cancer consultations between cancer patients and their treating clinicians. This study seeks to assess the patient experience in cancer care by observing patients and their physicians in their clinical interactions and following them for several months to see how their care went. By describing in-depth the conversations and experiences of patients in these clinical interactions, this study will lay the foundation for practice-based interventions to optimize patients' interactions with their cancer care teams.

NCT ID: NCT01129310 Completed - Clinical trials for Gastric Adenocarcinoma

First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

IXOGoo1
Start date: July 2010
Phase: Phase 2
Study type: Interventional

The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.

NCT ID: NCT00640692 Withdrawn - Clinical trials for Gastrointestinal Neoplasm

Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial

Start date: December 2007
Phase:
Study type: Observational

The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial. Tumor samples will be screened for mutations and this information will be used to determine whether the progression-free survival of patients being treated with the cancer medication sunitinib is related to the underlying genotype of their GIST.